Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — TSN ASX Gems Conference (March 2025)
16 slides from Optiscan Imaging's conference presentation, Mar 28, 2025
Slide 1: The new standard in digital pathology and precision surgery
For personal use only The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) 28 March 2025 This presentation has been approved by the Board of Optiscan for market release.
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 28 March 2025, and approved by the Board of Optiscan for market release. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contai
Slide 3: Optiscan at a Glance
Optiscan at a Glance A global medical technology company leading the transformation of digital pathology and precision surgery For personal use only ASX: OIL Melbourne $120m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office &
Slide 4: The Optiscan Opportunity
The Optiscan Opportunity For personal use only Artificial Intelligence $20.9 billion Clinical Life $10 trillion Sciences $144 billion Veterinary $46.51 billion Surgery $45.4 bn $US from referenced sources available on request.
Slide 5: Strategic Transformation
Strategic Transformation Governance OEM to PLM Compliance For personal use only Operations Manufacturing Clinical Regulatory Commercial Optiscan Hardware Mayo Clinic Software Uni Mainz Telepath Uni Minnesota Vet AI Uni Monash Strategic Diversified Medical RMH Partnerships Portfolio Veterinary Proluc
Slide 6: Diversified Hardware & Software Portfolio
Diversified Hardware & Software Portfolio Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Device
Slide 7: Progress to date
Progress to date o Sales & marketing appointments in AU For personal use only o InVue® reveal (Surgery) Artificial Intelligence and US o Defined regulatory pathway for InVue® o Outsourced business development in EU Q3FY25 o Renewed distributor agreements in APAC o InForm® reveal (Pathology) o ViewnV
Slide 8: Expanding Product Range - Clinical & Life Sciences
Expanding Product Range - Clinical & Life Sciences Oral Life Sciences Surgical Pathology For personal use only
Slide 9: Product Pipeline - By Development Stage
Product Pipeline - By Development Stage Application Stage Collaborators For personal use only Veterinary IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH MONITORING Surgical CLINICAL REGULATORY IDEATION PROTOTYPING PRECLINICAL LAUNCH MONITORING 2025-2026 2027 Pathology IDEA
Slide 10: Growing Footprint & Sales Pipeline
Growing Footprint & Sales Pipeline For personal use only European Union Business Development Sales & Marketing Beijing, China Distribution Sinsi Technologies Ltd Rochester MN, United States Regional Office Clinical & Regulatory Business Development Sales & Marketing Shanghai, China Distribution Biot
Slide 11: FY24 Financial Highlights
FY24 Financial Highlights Strong capital position and increased income. For personal use only Cash and Term Deposits $16.7m capital raised to advance multiple R&D projects $M 12 Balance sheet in FY24 remained strong with a cash and term deposit 10 balance of $11.2m 8 6 Balance as of Feb25 remain
Slide 12: FY25 Market Update
FY25 Market Update Projected increased revenue from sales and other income. For personal use only Revenue and Other Income FY25 Total Income (Revenue & Other Income) projected to increase up to 20%, approximately $4.2m from FY24 Revenue Other Income Revenue from sale of products $M 5 FY25 revenue
Slide 13: Positioned for Growth
Positioned for Growth For personal use only Phase 1: Core foundation Phase 2: Strategic transformation Phase 3: Strategic growth o Strategic focus o Digital health solutions o Develop core platform leader and initial product o Optimised operations offering o Full suite of digital health o Investment
Slide 14: Optiscan Investment Opportunity
Optiscan Investment Opportunity Value Proposition For personal use only Revolutionary Patent- Versatility of Platform & Diversified Hardware & Limitless Growth Potential Protected Technology Global Applications Software Offerings Market Differentiators & Investment Thesis Competitive High Barrier To
Slide 15: Contact Us
Contact Us For personal use only Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director, Optiscan Imaging Ltd (ASX:OIL) President & CEO, Optiscan Imaging, Inc. cfarah@optiscan.com /company/Optiscan www.optiscan.com
Slide 16: For personal use only
O Optiscan Ajuo asn yeuossad 104
Optiscan Imaging — TSN ASX Gems Conference (March 2025) on 6ix